Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Energized Biogen Idec On Track For Two Filings In 2012

This article was originally published in The Pink Sheet Daily

Executive Summary

Biogen hopes to submit marketing applications in the U.S. and Europe for both MS therapy BG-12 and its therapies for hemophilia A and B in 2012, with launches possible in early and mid-2013.

You may also be interested in...



BG-12 In MS, Two Long-Acting Hemophilia Drugs Key To Scangos’ Revitalized Biogen Idec

An R&D overhaul trimmed 17 candidates from pipeline, but as several late-stage programs near potential approval, the biotech says it will resume focus on discovery and validation of new targets.

BG-12 In MS, Two Long-Acting Hemophilia Drugs Key To Scangos’ Revitalized Biogen Idec

An R&D overhaul trimmed 17 candidates from the pipeline, but as several late-stage programs near potential approval, the biotech says it will resume focus on discovery and validation of new targets.

Biogen Idec Buys Stromedix, Bringing IPF Candidate Full Circle

Started by a former Biogen executive, Stromedix licensed STX-100 from Biogen and developed it into an attractive candidate in an area the reshaped big biotech wants to pursue.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS073325

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel